Cantor Fitzgerald Comments on REGN FY2025 Earnings

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) – Analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Regeneron Pharmaceuticals in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst O. Brayer forecasts that the biopharmaceutical company will post earnings per share of $38.93 for the year. Cantor Fitzgerald currently has a “Neutral” rating and a $1,015.00 price target on the stock. The consensus estimate for Regeneron Pharmaceuticals’ current full-year earnings is $37.72 per share.

REGN has been the subject of several other reports. Bank of America reissued an “underperform” rating and set a $565.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 10th. Evercore ISI cut their target price on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. Barclays decreased their price target on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. Leerink Partnrs cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Finally, Oppenheimer decreased their target price on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $1,015.38.

Regeneron Pharmaceuticals Stock Up 0.9 %

Shares of Regeneron Pharmaceuticals stock opened at $687.80 on Wednesday. The company has a market cap of $75.58 billion, a P/E ratio of 17.02, a PEG ratio of 1.61 and a beta of 0.10. The firm has a fifty day moving average of $735.72 and a two-hundred day moving average of $946.39. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. Regeneron Pharmaceuticals has a one year low of $666.25 and a one year high of $1,211.20.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Several hedge funds have recently made changes to their positions in the business. State Street Corp grew its holdings in Regeneron Pharmaceuticals by 1.3% in the 3rd quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock valued at $5,153,603,000 after buying an additional 61,277 shares during the period. International Assets Investment Management LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 86,013.3% in the 3rd quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after purchasing an additional 879,916 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Regeneron Pharmaceuticals by 1.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 673,261 shares of the biopharmaceutical company’s stock valued at $707,759,000 after buying an additional 11,499 shares during the period. The Manufacturers Life Insurance Company increased its holdings in shares of Regeneron Pharmaceuticals by 0.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 340,566 shares of the biopharmaceutical company’s stock worth $357,945,000 after buying an additional 2,270 shares during the last quarter. Finally, Swiss National Bank grew its position in Regeneron Pharmaceuticals by 0.6% during the third quarter. Swiss National Bank now owns 321,600 shares of the biopharmaceutical company’s stock valued at $338,079,000 after acquiring an additional 2,000 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.